Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing

Clinical Cancer Research

Volumn 19, Issue 3, 2013, Pages 691-698

  Buttitta, Fiamma ^a   Felicioni, Lara ^a   Del Grammastro, Maela ^a   Filice, Giampaolo ^a   Di Lorito, Alessia ^a   Malatesta, Sara ^a   Viola, Patrizia ^a   Centi, Irene ^b   D'Antuono, Tommaso ^b   Zappacosta, Roberta ^a   Rosini, Sandra ^a   Cuccurullo, Franco ^a   Marchetti, Antonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ss Annunziata Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER SURGERY; CONTROLLED STUDY; CYTOLOGY; DNA SEQUENCE; EGFR GENE; FEASIBILITY STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG LAVAGE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; PLEURA FLUID; PRIORITY JOURNAL; SANGER SEQUENCE; TUMOR CELL;

ADENOCARCINOMA; BRONCHOALVEOLAR LAVAGE FLUID; DNA MUTATIONAL ANALYSIS; EXONS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MUTATION; PLEURAL EFFUSION, MALIGNANT; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84873395134     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1958     Document Type: Article

References (33)

1. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go? Nat Rev Clin Oncol 2011; 9:87-97.
2. Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, O'Byrne K. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. J Clin Pathol 2012;65:1-7.
3. Mitsudomi T. Erlotinib, gefitinib, or chemotherapy for EGFR mutationpositive lung cancer? Lancet Oncol 2011;12:710-1.
4. Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, et al. EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. J Thorac Oncol 2012;7:672-80.
5. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010;5:1706-13.
6. Marchetti A, Normanno NAIOM-SIAPEC-IAPPinto C, Taddei GL, Adamo V, et al. Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 2010;102:119-26.
7. Eberhard DA, Giaccone G, Johnson BE. Non-Small-Cell Lung Cancer Working Group. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-94.
8. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011;119:80-91
9. Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411-4.
10. Rekhtman N, Brandt SM, Sigel CS, Friedlander MA, Riely GJ, Travis WD, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011;6:451-8.
11. Malapelle U, Bellevicine C, Zeppa P, Palombini L, Troncone G. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol 2011; 39:703-10.
12. Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009; 117:67-72.
13. Hlinkova K, Babal P, Berzinec P, Majer I, Ilencikova D. Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis. Mol Diagn Ther 2011;15: 21-9.
14. Linder J. Lung cancer cytology. Something old, something new. Am J Clin Pathol 2000 114:169-71.
15. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006;354:526-8; author reply 526-8.
16. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008;9:387-402.
17. Schuster SC. Next-generation sequencing transforms today's biology. Nat Methods 2008;5:16-18.
18. Metzker ML. Sequencing technologies-the next generation. Nat Rev Genet 2010;11:31-46.
19. Corless CL, Spellman PT. Tackling formalin-fixed, paraffin-embedded tumor tissue with next-generation sequencing. Cancer Discov 2012;2: 23-4
20. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-6
21. Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006;12: 852-55.
22. Querings S, Altmuller J, Ansén S, Zander T, Seidel D, Gabler F, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 2011;6:e19601.
23. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol 2011;119:111-7.
24. Thunnissen E, Kerr KM, Herth FJ, Lantuejoul S, Papotti M, Rintoul RC, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012;76:1-18.
25. Nomoto K, Tsuta K, Takano T, Fukui T, Yokozawa K, Sakamoto H, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006;126:608-15.
26. Fassina A, Gazziero A, Zardo D, Corradin M, Aldighieri E, Rossi GP. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol 2009;62:1096-102.
27. Kanaji N, Bandoh S, Ishii T, Kushida Y, Haba R, Kohno K, et al. Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction. Mol Diagn Ther 2011;15: 353-9.
28. Kawahara A, Azuma K, Sumi A, Taira T, Nakashima K, Aikawa E, et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011;74: 35-40.
29. van Eijk R, Licht J, Schrumpf M, Talebian Yazdi M, Ruano D, Forte GI, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One 2011;6:e17791.
30. Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, et al. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007;131: 1628-34.
31. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
32. Di Lorito A, Schmitt FC. (Cyto)pathology and sequencing: next (or last) generation? Diagn Cytopathol 2012;40:459-61.
33. Marchetti A, Del Grammastro M, Filice G, Felicioni L, Rossi G, Graziano P, et al. Complex mutations and subpopulations of deletions at exon 19 of EGFR in lung tumors revealed by new generation sequencing: clinical implications. PLoS One 2012;7:e42164.